Daix (France), Long Island City (New York, United States), May 21, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a biopharmaceutical company specializing in the clinical development of small molecules administered by oral route for the treatment of steatohepatitis associated with metabolic dysfunction (“MASH”), also known as nonalcoholic steatohepatitis (“NASH”) and other diseases with a significant unmet medical need, publishes today its financial information including its cash position as of March 31, 2024 and its turnover, and provides an update on its activities.